Antidepressant drug use in glioblastoma patients: an epidemiological view.
antidepressants
depression
epidemiology
glioblastoma
survival
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
Antidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized on a population level. Patient characteristics, including the frequency of antidepressant drug use, were assessed in a glioblastoma cohort diagnosed in a 10-year time frame between 2005 and 2014 in the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival (OS) data and the log-rank test was performed for comparisons. A total of 404 patients with isocitrate dehydrogenase wild-type glioblastoma were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point during the disease course. Patients were most commonly prescribed selective serotonin reuptake inhibitors at any time (N = 46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at the time of their tumor diagnosis. No differences were observed in OS between those patients who had taken antidepressants at some point in their disease course and those who had not ( This signal-seeking study does not support the hypothesis that antidepressants have antitumor efficacy in glioblastoma on a population level.
Sections du résumé
BACKGROUND
BACKGROUND
Antidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized on a population level.
METHODS
METHODS
Patient characteristics, including the frequency of antidepressant drug use, were assessed in a glioblastoma cohort diagnosed in a 10-year time frame between 2005 and 2014 in the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival (OS) data and the log-rank test was performed for comparisons.
RESULTS
RESULTS
A total of 404 patients with isocitrate dehydrogenase wild-type glioblastoma were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point during the disease course. Patients were most commonly prescribed selective serotonin reuptake inhibitors at any time (N = 46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at the time of their tumor diagnosis. No differences were observed in OS between those patients who had taken antidepressants at some point in their disease course and those who had not (
CONCLUSIONS
CONCLUSIONS
This signal-seeking study does not support the hypothesis that antidepressants have antitumor efficacy in glioblastoma on a population level.
Identifiants
pubmed: 33014392
doi: 10.1093/nop/npaa022
pii: npaa022
pmc: PMC7516105
doi:
Types de publication
Journal Article
Langues
eng
Pagination
514-521Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Curr Med Chem. 2012;19(5):675-82
pubmed: 22204340
Cancer Cell. 2007 Jan;11(1):37-51
pubmed: 17222789
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 28252230
Anticancer Res. 2010 Feb;30(2):391-7
pubmed: 20332444
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
Neurology. 2006 Jan 24;66(2):239-42
pubmed: 16434662
Cancer. 2016 Jul 15;122(14):2206-15
pubmed: 27088883
Korean J Physiol Pharmacol. 2017 Jul;21(4):415-421
pubmed: 28706455
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
BMC Cancer. 2015 Nov 03;15:839
pubmed: 26530050
Breast Cancer Res Treat. 2001 Nov;70(1):1-10
pubmed: 11766999
J Neurooncol. 2019 Mar;142(1):183-191
pubmed: 30680509
Cancer Cell. 2015 Oct 12;28(4):456-471
pubmed: 26412325
Curr Oncol Rep. 2019 May 2;21(6):55
pubmed: 31049786
Biochem Biophys Res Commun. 2011 Sep 23;413(2):311-7
pubmed: 21889492
Biomedicines. 2017 Jun 09;5(2):
pubmed: 28598356
Cancer Treat Rev. 2018 Jul;68:145-154
pubmed: 30032756
Ann Oncol. 2018 Jun 1;29(6):1431-1436
pubmed: 29617713
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Biochem Biophys Res Commun. 2018 May 27;500(1):51-58
pubmed: 28642134
Neurosurgery. 2004 Feb;54(2):358-66; discussion 366-7
pubmed: 14744282
J Neurooncol. 2019 Dec;145(3):487-499
pubmed: 31637628
Am J Clin Oncol. 2011 Aug;34(4):385-7
pubmed: 20859197
J Natl Cancer Inst. 2011 Jan 5;103(1):61-76
pubmed: 21106962
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Br J Neurosurg. 1999 Oct;13(5):480-5
pubmed: 10627779
Oncotarget. 2015 Mar 10;6(7):5088-101
pubmed: 25671301
Cancer Control. 2018 Jan-Dec;25(1):1073274818798594
pubmed: 30213208
Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76
pubmed: 18425006
Neuro Oncol. 2019 Nov 4;21(11):1447-1457
pubmed: 31682733
Neurooncol Pract. 2019 May;6(3):237-244
pubmed: 31386047
Oncotarget. 2012 May;3(5):516-7
pubmed: 22695512
ESMO Open. 2019 Jun 17;4(Suppl 2):e000520
pubmed: 31297242